475P Dynamics of TROP2 expression in triple-negative breast cancer
Ana C. Garrido-Castro(Dana-Farber Cancer Institute), Elza C. de Bruin(AstraZeneca (United Kingdom)), Elizabeth A. Mittendorf(Beth Israel Deaconess Medical Center), Ayesha Mohammed-Abreu(Dana-Farber Cancer Institute), Jorge Gómez Tejeda Zañudo(Broad Institute), Danielle Carroll(AstraZeneca (United Kingdom)), Nancy U. Lin(Dana-Farber Cancer Institute), José‐Tomás Navarro(Universitat Autònoma de Barcelona), Sara M. Tolaney(Harvard University), Busem Binboğa Kurt(Dana-Farber Cancer Institute), Tari A. King(Brigham and Women's Hospital), Alice Barkell(AstraZeneca (United Kingdom)), R. J. Hill, Antonio H. Frangieh(Deutsches Herzzentrum München), Marlon C. Rebelatto(AstraZeneca (Japan)), Melissa E. Hughes(Dana-Farber Cancer Institute)
Cited by 2
Related Papers
Tumour exosome integrins determine organotropic metastasis
|Nature|2015|5.2k
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
|Cancer Discovery|2019|1.4k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k